Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Response Genetics To Present New Data On Lung Cancer Supporting The Use Of Gene Expression To Help Personalize Cancer Therapy Selection
Response Genetics Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, will announce the results of separate analyses of KRAS gene mutations and TS and RRM1 gene expression in non-small cell lung cancer (NSCLC) during the 13th World Conference on Lung Cancer, which will be held July 31 to August 4. Results will provide insights into which patient subtypes are most likely to benefit from the commonly prescribed chemotherapies pemetrexed and gemcitabine.
generic viagra online
Atrial Fibrillation Linked To Increased Hospitalization In Heart Failure Patients
Patients with atrial fibrillation, common in those with advanced chronic heart failure, have an increased risk of hospitalization due to heart failure, according to new research from researchers at the University of Alabama at Birmingham (UAB). The findings, published in June in the European Heart Journal, also suggest that atrial fibrillation is not associated with an increased risk of death in heart failure patients, contradicting previous assumptions.
News of the day
Possible Benefit From Online Genetic Testing For Lung Cancer
As scientists continue to decode the human genome and the information becomes publicly available, private companies that offer online genetic testing are multiplying. Scientists at the National Institutes of Health were concerned that perhaps these tests posed a risk.
Diagnostics

Independent Study Confirms Superior Properties Of ZPC(TM) Enhanced Calcium Composite Bone Grafts

A recent independent study has confirmed Fortoss Vital(R), developed by the Pioneering Orthobiologics Company, Biocomposites, as an effective bone replacement material demonstrating superior bone regenerative properties due to its unique negative zeta potential control (ZPC(TM)). The research carried out by the hospital and departments of the university of Aachen and the Universities of Munich and Regensburg, Germany, analysed the osteogenic potential of Fortoss Vital for maxillary sinus floor augmentation on a 61 year old female. The samples taken from the graft site at 6 months, showed the negative surface charge of Fortoss Vital had accelerated the bone formation cascade and rapidly produced mature lamellar bone formation with marrow cavities. The bone density at the graft site was shown to be denser than the original bone matrix of the posterior maxillary region. Evidence also confirmed the complete resorption of Fortoss Vital. Fortoss Vital is a unique, bi-phasic calcium composite bone graft material having a negative surface charge which attracts the key proteins and cells for rapid osteogenesis and bone repair. Fortoss Vital is fully resorbed by osteoclastic processes and replaced by bone. Biocomposites" Managing Director Stephen Bratt said, "This independent clinical data in a maxillofacial indication, corroborates similar orthopaedic studies confirming that Biocomposites" ZPC technology, with a unique surface chemistry accelerates bone growth. About the company: Biocomposites is a privately held, leading developer, manufacturer and distributor of synthetic, tissue regeneration products. Since 1997, the company has developed a broad range of products that addresses the clinical and economic needs of medical specialties in orthopaedics and dentistry. Research, manufacturing, sales and marketing are directed from the company"s headquarters in Keele, Staffordshire, UK. Biocomposites also has two subsidiary companies, based in Shanghai, P.R.China and Wilmington, North Carolina, USA. Fortoss Vital(R) and Biocomposites(R) The Next Regeneration(TM) are registered trademarks of Biocomposites Ltd. Referenes: Smeets et al. " A new biphasic osteoinductive calcium composite material with a negative Zeta potential for bone augmentation." Head & face Medicine 2009, 5:13 doi:10.1186/1746-160X-5-13. Biocomposites Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009